340B
Manufacturer updates
AbbVie
Contact:
April 11th, 2023
Amgen
Effective April 11th, 2023, Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.
January 3rd, 2022
Amgen
Contact:
January 1st, 2021
Amgen
Contact:
340Brelations@amgen.com
June 1st, 2022
AstraZeneca
*Calquence & Lynparza (October 1st, 2022) and Fasenra (January 1st, 2023) voluntary contracts restored.
October 1st, 2020
AstraZeneca
Effective October 1st, 2020, AstraZeneca will only provide 340B priced product to a single Contract Pharmacy.
Contact: membership@AstraZeneca.com
Bausch Health
Effective August 1st, 2022, Bausch Health will only provide 340B priced product to a single Contract Pharmacy if Covered Entity doesn’t have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP.
Contact:
support@340Besp.com
Bayer
Effective March 1, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy location if the hospital Covered Entity does not have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. Grantees not subject to limitations.
Biogen
Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if the Covered Entity does not have an in-house pharmacy. Policy is limited to two drugs and doesn’t include Federal Grantees.
September 1st, 2022
Boehringer Ingelheim
Boehringer Ingelheim announced effective September 1st, 2022, an expansion to their contract pharmacy policy to include grantees enrolled in the Consolidated Health Center Program (CH/CHC). All other Federal Grantees not subject to limitations.
Contact:
support@340besp.com
December 1st, 2021
Boehringer Ingelheim
Effective December 1st, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions from August 1st, 2021, remain effective. Link to both notices below.
Contact:
support@340Besp.com
Bristol Myers Squibb
*Camzyos effective July 1st, 2022
Clovis
At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.
Contact:
priceadmin@clovisoncology.com
December 10th, 2021
Eli Lilly
Contact:
340B@lilly.com
September 1st, 2020
Eli Lilly
Effective September 1st, 2020, Lilly restricted access for 340B priced product to Contract Pharmacies, except insulin.
Contact:
340B@lilly.com
EMD Serono
Effective March 1, 2023, EMD Serono (EMDS) will only provide 340B pricing for REBIF and GONAL-F to a single Contract Pharmacy if a hospital Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.
Exelixis
Contact:
340B@exelixis.com
Gilead
July 1st, 2022
GlaxoSmith Kline
Effective July 1st, 2022, GSK will no longer offer voluntary 340B pricing on two orphan drugs (NUCALA and ZEJULA) to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact Covered Entities not subject to the orphan drug exclusion.
Contact:
US.340B@gsk.com
April 1st, 2022
GlaxoSmith Kline
Contact
March 7th, 2023
Janssen
Contact:
May 31st, 2022
Merck
Contact:
September 1st, 2021
Merck
Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.
Contact:
340Bdata@merck.com
Novartis
Contact: Novartis.340B@novartis.com
December 2nd, 2022
Novo Nordisk
Contact:
January 24th, 2022
Novo Nordisk
January, 1st 2021
Novo Nordisk
Contact: 340BInfo@novonordisk.com
Pfizer
Sanofi
Contact: Sanofi340Boperations@sanofi.com
UCB
Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.
Contact:
support@340Besp.com
United Therapeutics
Contact:
340B@unither.com
Woodward
Effective April 1, 2023, select Woodward Pharma products will only be available at a 340B ceiling price through direct distribution via DCS and no longer available via full line distributor 340B accounts.
*12 additional NDCs effective March 15th, 2023
Contact:
340b-clientsservices@
directcustomersolutions.com